GlassScriptPhysician profile
Steven P Glusman
NPI 1275530974
$2,889.80
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,140 · 2021: $72.31 · 2022: $119 · 2023: $315 · 2024: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $558.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $537.15 | 2019 | |
| Alexion Pharmaceuticals, INC. | $354.01 | 2019-2023 | Soliris |
| Medtronic USA, INC. | $270.56 | 2019 | |
| Emd Serono, INC. | $257.08 | 2019-2023 | Mavenclad |
| Medtronic, INC. | $241.09 | 2021-2024 | Percept PC Brainsense |
| Genzyme Corporation | $192.87 | 2019 | |
| Eisai INC. | $144.92 | 2019 | |
| Amneal Pharmaceuticals LLC | $137.13 | 2019 | |
| Novartis Pharmaceuticals Corporation | $129.00 | 2019 | |
| Argenx US, INC. | $121.84 | 2024 | Vyvgart |
| Neurocrine Biosciences, INC. | $116.86 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $114.93 | 2019 | |
| Genentech USA, INC. | $109.76 | 2019 | |
| Abbvie INC. | $87.98 | 2019-2024 | |
| Sunovion Pharmaceuticals INC. | $19.55 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $18.55 | 2019 | |
| Genentech, INC. | $12.97 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.90 | 2019 | |
| Ucb, INC. | $11.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Glusman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.